NO992309L - FremgangsmÕte for anvendelse av cyklooksygenase-2 inhibitorer som anti-angiogene midler - Google Patents

FremgangsmÕte for anvendelse av cyklooksygenase-2 inhibitorer som anti-angiogene midler

Info

Publication number
NO992309L
NO992309L NO992309A NO992309A NO992309L NO 992309 L NO992309 L NO 992309L NO 992309 A NO992309 A NO 992309A NO 992309 A NO992309 A NO 992309A NO 992309 L NO992309 L NO 992309L
Authority
NO
Norway
Prior art keywords
cyclooxygenase
inhibitors
angiogenic agents
angiogenic
agents
Prior art date
Application number
NO992309A
Other languages
English (en)
Norwegian (no)
Other versions
NO992309D0 (no
Inventor
Jaime L Masferrer
Amiram Raz
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of NO992309D0 publication Critical patent/NO992309D0/no
Publication of NO992309L publication Critical patent/NO992309L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
NO992309A 1996-11-19 1999-05-12 FremgangsmÕte for anvendelse av cyklooksygenase-2 inhibitorer som anti-angiogene midler NO992309L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3140496P 1996-11-19 1996-11-19
PCT/US1997/021489 WO1998022101A2 (en) 1996-11-19 1997-11-19 Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents

Publications (2)

Publication Number Publication Date
NO992309D0 NO992309D0 (no) 1999-05-12
NO992309L true NO992309L (no) 1999-05-12

Family

ID=21859277

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992309A NO992309L (no) 1996-11-19 1999-05-12 FremgangsmÕte for anvendelse av cyklooksygenase-2 inhibitorer som anti-angiogene midler

Country Status (19)

Country Link
EP (1) EP0941080A2 (ro)
JP (1) JP2001505564A (ro)
KR (1) KR20000053362A (ro)
CN (1) CN1247470A (ro)
AU (1) AU730211B2 (ro)
BR (1) BR9713522A (ro)
CA (1) CA2270469C (ro)
CZ (1) CZ176899A3 (ro)
ID (1) ID21979A (ro)
IL (1) IL129604A (ro)
NO (1) NO992309L (ro)
NZ (1) NZ335853A (ro)
PL (2) PL194717B1 (ro)
RO (1) RO118566B1 (ro)
RU (1) RU2268716C2 (ro)
SK (1) SK59999A3 (ro)
TR (1) TR199901703T2 (ro)
UA (1) UA70294C2 (ro)
WO (1) WO1998022101A2 (ro)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AU2593600A (en) * 1998-12-23 2000-07-12 G.D. Searle & Co. Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia
WO2000053149A2 (en) * 1999-03-10 2000-09-14 G.D. Searle & Co. Method and composition for administering a cyclooxygenase-2 inhibitor
EP1206256B8 (en) * 1999-07-29 2005-06-29 Amgen, Inc. Combination therapy using pentafluorobenzenesulfonamide and platin compound
AU6469401A (en) * 2000-05-19 2001-11-26 Serono Reproductive Biology In Pharmaceutically active compounds and methods of use
AU2002234165A1 (en) 2000-11-03 2002-05-27 Tularik, Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
KR100686537B1 (ko) * 2001-12-28 2007-02-27 씨제이 주식회사 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체
CA2492387A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric carboxylic of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
KR100484525B1 (ko) * 2002-10-15 2005-04-20 씨제이 주식회사 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
AT504159A1 (de) * 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc Verwendung von proteasen
RU2475257C1 (ru) * 2011-06-22 2013-02-20 Людмила Николаевна Третьяк Средство для повышения адаптируемости организма к экстремальным условиям
GB2496135B (en) * 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297592A1 (en) * 1993-01-15 1994-07-21 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
CN1061036C (zh) * 1993-11-30 2001-01-24 G·D·瑟尔公司 用于治疗炎症的取代的吡唑基苯磺酰胺类化合物
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
EP0799218B1 (en) * 1994-12-21 2003-02-19 Merck Frosst Canada & Co. Diaryl-2-(5h)-furanones as cox-2 inhibitors
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors

Also Published As

Publication number Publication date
KR20000053362A (ko) 2000-08-25
ID21979A (id) 1999-08-19
JP2001505564A (ja) 2001-04-24
PL333370A1 (en) 1999-12-06
CZ176899A3 (cs) 1999-10-13
SK59999A3 (en) 2000-01-18
IL129604A0 (en) 2000-02-29
IL129604A (en) 2004-08-31
BR9713522A (pt) 2000-03-21
WO1998022101A3 (en) 1998-06-25
UA70294C2 (en) 2004-10-15
EP0941080A2 (en) 1999-09-15
TR199901703T2 (xx) 2000-07-21
NO992309D0 (no) 1999-05-12
NZ335853A (en) 2002-02-01
AU730211B2 (en) 2001-03-01
PL194717B1 (pl) 2007-06-29
CA2270469A1 (en) 1998-05-28
PL191793B1 (pl) 2006-07-31
CN1247470A (zh) 2000-03-15
RO118566B1 (ro) 2003-07-30
CA2270469C (en) 2007-04-10
AU7298298A (en) 1998-06-10
WO1998022101A2 (en) 1998-05-28
RU2268716C2 (ru) 2006-01-27

Similar Documents

Publication Publication Date Title
DK0818448T3 (da) Cycloalkanopyridiner som CETP-inhibitorer
NO995077L (no) Fremgangsmåte ved anvendelse av cyklooksygenase-2 inhibitorer
DK1049695T3 (da) 2-Phenyl-substituerede imidazotriazinoner som phosphodiesterase-inhibitorer
NO954427D0 (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
NO992821D0 (no) Ketobenzamider som calpain-inhibitorer
FI962800A (fi) Fenyyliheterosyklisiä yhdisteitä COX-2 inhibiittoreina
NO992309L (no) FremgangsmÕte for anvendelse av cyklooksygenase-2 inhibitorer som anti-angiogene midler
NO992725D0 (no) 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer
ID23983A (id) Inhibitor-inhibitor aminotiazol untuk kinase-kinase tergantung siklin
DK0912518T3 (da) Substituerede pyridiner som selektive cyclooxygenase-2 inhibitorer
NO20021042L (no) Benzofenoner som inhibitorer av reverstranskriptaser
FI944804A0 (fi) Pyrimidinyyliasetamideja elastaasin estäjinä
FI971104A0 (fi) Menetelmä COX-inhibiittoreina käyttökelpoisten fenyyliheterosyklien valmistamiseksi
NO940305D0 (no) Kinazolin-derivater som acetylcholin-esteraseinhibitorer
DK0593294T3 (da) Aminderivater som korrosionsinhibitorer
DK0912537T3 (da) Fremgangsmåde til fremstilling af phenylheterocykliske forbindelser, der er anvendelige som cox-2-inhibitorer
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
NO20010331L (no) Ftalazinderivater som fosfodiesterase 4-inhibitorer
NO20001924D0 (no) Isoquinoliner som urokinase-inhibitorer
DE69523961D1 (de) Beta-Carbolin Thromboxansynthase Inhibitoren
NO922167L (no) Aminodukter som korrosjonshemmere
NO911459D0 (no) Anvendelse av metallion-komplekser som belegginhibitorer.
EE04750B1 (et) HIV-proteaasi inhibiitorite valmistamismeetod
NO983227L (no) Blandinger som vesentlig bestÕr av polyetylen, samt fremgangsmÕte for Õ fre
ID26703A (id) Penggunaan anestesi lokal untuk sakit kepala vaskular

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application